| |

January 17-22 · Grand Hyatt Kauai · Kauai, Hawaii |
 |
 |
Learn how to apply new diagnostic and
treatment modalities to your practice
|
|
| |
| Educational Objectives |
|
| At the conclusion of this activity, attendees should be able to: |
|
- Discuss the pathogenesis and treatment of dry age-related macular degeneration; provide insights on nutritional therapy, imaging techniques, and new medications
- Explain the use of anti-VEGF agents, as well as optimal dosing strategies, for the treatment of choroidal neovascularization in wet age-related macular degeneration
- Analyze a review of the latest developments in vitreoretinal surgery technology, drug delivery, and artificial vision used to improve patient outcomes
- Define new developments in the management of retinal detachment in both adults
and children
|
|
| |
|
|
|
| |
|
|
|
| This continuing medical education activity is jointly sponsored by |
Held in conjunction with |
|
 |
and |
|
|
|
|
| |
|
ACCREDITATION: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Vindico Medical Education and Ocular Surgery News®. Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
This activity has been approved for AMA PRA Category 1 Credits™.
FACULTY/PLANNER DISCLOSURE POLICY: In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all planners, teachers, and authors involved in the development of CME content are required to disclose to the accredited provider their relevant financial relationships. Relevant financial relationships will be disclosed to the activity audience.
NOTICE: Faculty, topics, program schedule and credit hours are subject to change. Audio taping or video taping is prohibited without written permission from the program director and the Office of Compliance and Regulatory Affairs.
|
|
|
| |
|
|
|
| |
|
|
|
|
|